183 related articles for article (PubMed ID: 17335002)
1. Examination of the decline in symptoms of anxiety and depression in generalized anxiety disorder: impact of anxiety sensitivity on response to pharmacotherapy.
Olatunji BO; Feldman G; Smits JA; Christian KM; Zalta AK; Pollack MH; Simon NM
Depress Anxiety; 2008; 25(2):167-71. PubMed ID: 17335002
[TBL] [Abstract][Full Text] [Related]
2. Treatment of depression and anxiety in infertile women: cognitive behavioral therapy versus fluoxetine.
Faramarzi M; Alipor A; Esmaelzadeh S; Kheirkhah F; Poladi K; Pash H
J Affect Disord; 2008 May; 108(1-2):159-64. PubMed ID: 17936366
[TBL] [Abstract][Full Text] [Related]
3. The effect of fluoxetine on anxiety and depression symptoms in cancer patients.
Razavi D; Allilaire JF; Smith M; Salimpour A; Verra M; Desclaux B; Saltel P; Piollet I; Gauvain-Piquard A; Trichard C; Cordier B; Fresco R; Guillibert E; Sechter D; Orth JP; Bouhassira M; Mesters P; Blin P
Acta Psychiatr Scand; 1996 Sep; 94(3):205-10. PubMed ID: 8891089
[TBL] [Abstract][Full Text] [Related]
4. Treatment of selective serotonin reuptake inhibitor-resistant depression in adolescents: predictors and moderators of treatment response.
Asarnow JR; Emslie G; Clarke G; Wagner KD; Spirito A; Vitiello B; Iyengar S; Shamseddeen W; Ritz L; Birmaher B; Ryan N; Kennard B; Mayes T; DeBar L; McCracken J; Strober M; Suddath R; Leonard H; Porta G; Keller M; Brent D
J Am Acad Child Adolesc Psychiatry; 2009 Mar; 48(3):330-339. PubMed ID: 19182688
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder.
Silverstone PH; Salinas E
J Clin Psychiatry; 2001 Jul; 62(7):523-9. PubMed ID: 11488362
[TBL] [Abstract][Full Text] [Related]
6. Psychic and somatic anxiety symptoms as predictors of response to fluoxetine in major depressive disorder.
Papakostas GI; McGrath P; Stewart J; Charles D; Chen Y; Mischoulon D; Dording C; Fava M
Psychiatry Res; 2008 Oct; 161(1):116-20. PubMed ID: 18755514
[TBL] [Abstract][Full Text] [Related]
7. Spotlight on paroxetine in psychiatric disorders in adults.
Wagstaff AJ; Cheer SM; Matheson AJ; Ormrod D; Goa KL
CNS Drugs; 2002; 16(6):425-34. PubMed ID: 12027788
[TBL] [Abstract][Full Text] [Related]
8. Fluoxetine treatment of depressed patients with comorbid anxiety disorders.
Sonawalla SB; Farabaugh A; Johnson MW; Morray M; Delgado ML; Pingol MG; Rosenbaum JF; Fava M
J Psychopharmacol; 2002 Sep; 16(3):215-9. PubMed ID: 12236627
[TBL] [Abstract][Full Text] [Related]
9. Fluoxetine tenth anniversary update: the progress continues.
Stokes PE; Holtz A
Clin Ther; 1997; 19(5):1135-250. PubMed ID: 9385500
[TBL] [Abstract][Full Text] [Related]
10. [The use of antidepressants to treat depression in children and adolescents].
Desombre H; Paccalin C; Revol O; Fourneret P
Arch Pediatr; 2006 Jun; 13(6):711-3. PubMed ID: 16697608
[No Abstract] [Full Text] [Related]
11. Hypochondriacal concerns in depressed outpatients.
Demopulos C; Fava M; McLean NE; Alpert JE; Nierenberg AA; Rosenbaum JF
Psychosom Med; 1996; 58(4):314-20. PubMed ID: 8827793
[TBL] [Abstract][Full Text] [Related]
12. Tiagabine for the treatment of generalized anxiety disorder: a randomized, open-label, clinical trial with paroxetine as a positive control.
Rosenthal M
J Clin Psychiatry; 2003 Oct; 64(10):1245-9. PubMed ID: 14658975
[TBL] [Abstract][Full Text] [Related]
13. Pharmacotherapy in depressed children and adolescents.
Taurines R; Gerlach M; Warnke A; Thome J; Wewetzer C
World J Biol Psychiatry; 2011 Sep; 12 Suppl 1():11-5. PubMed ID: 21905988
[TBL] [Abstract][Full Text] [Related]
14. Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study.
Pollack MH; Simon NM; Zalta AK; Worthington JJ; Hoge EA; Mick E; Kinrys G; Oppenheimer J
Biol Psychiatry; 2006 Feb; 59(3):211-5. PubMed ID: 16139813
[TBL] [Abstract][Full Text] [Related]
15. The patient with comorbid depression and anxiety: the unmet need.
Bakish D
J Clin Psychiatry; 1999; 60 Suppl 6():20-4. PubMed ID: 10235121
[TBL] [Abstract][Full Text] [Related]
16. An open-label study to evaluate switching from an SSRI or SNRI to tiagabine to alleviate antidepressant-induced sexual dysfunction in generalized anxiety disorder.
Schwartz TL; Nasra GS; Ashton AK; Kang D; Kumaresan H; Chilton M; Bertone F
Ann Clin Psychiatry; 2007; 19(1):25-30. PubMed ID: 17453658
[TBL] [Abstract][Full Text] [Related]
17. Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression.
Fava M; Rosenbaum JF; Hoog SL; Tepner RG; Kopp JB; Nilsson ME
J Affect Disord; 2000 Aug; 59(2):119-26. PubMed ID: 10837880
[TBL] [Abstract][Full Text] [Related]
18. Preliminary support for gender differences in response to fluoxetine for generalized anxiety disorder.
Simon NM; Zalta AK; Worthington JJ; Hoge EA; Christian KM; Stevens JC; Pollack MH
Depress Anxiety; 2006; 23(6):373-6. PubMed ID: 17068858
[TBL] [Abstract][Full Text] [Related]
19. Personality disorder scores improve with effective pharmacotherapy of depression.
Black KJ; Sheline YI
J Affect Disord; 1997 Mar; 43(1):11-8. PubMed ID: 9127826
[TBL] [Abstract][Full Text] [Related]
20. Discontinuation symptoms: comparison of brief interruption in fluoxetine and paroxetine treatment.
Judge R; Parry MG; Quail D; Jacobson JG
Int Clin Psychopharmacol; 2002 Sep; 17(5):217-25. PubMed ID: 12177584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
